Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (131-140 of 785) with videos related to

Pageof 79
Sort By:
Kidney & Blood Pressure Research|March 4, 2010
Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantationKai Lopau, Karin Syamken, Peter Rubenwolf, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|March 1, 2023
Clinical performance comparison of two medium cut-off dialyzersDetlef H Krieter, Marieke Rüth, Horst-Dieter Lemke, et al.
European Heart Journal|February 17, 2018
Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapyJonas Müntze, Tim Salinger, Daniel Gensler, et al.
International Journal of Cardiology|August 8, 2006
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trialsHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 20, 2015
Fabry disease and the heartNora Seydelmann, Christoph Wanner, Stefan Störk, et al.
Renal Failure|August 25, 2006
The renal safety profile of fluvastatin: results of a pooled analysisHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
BMC Medical Research Methodology|June 7, 2011
Understanding competing risks: a simulation point of viewArthur Allignol, Martin Schumacher, Christoph Wanner, et al.
Nephron|July 18, 2015
Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with HyperphosphatemiaJoachim Hertel, Francesco Locatelli, Goce Spasovski, et al.
Circulation|December 2, 2009
Glycemic control and cardiovascular events in diabetic hemodialysis patientsChristiane Drechsler, Vera Krane, Eberhard Ritz, et al.
BMC Medical Genetics|July 20, 2016
Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation allelesDaniel Oder, Dorothee Vergho, Georg Ertl, et al.
Pageof 79

Showing results (131-140 of 785) with videos related to

Sort By:
Pageof 79
Kidney & Blood Pressure Research|March 4, 2010
Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantationKai Lopau, Karin Syamken, Peter Rubenwolf, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|March 1, 2023
Clinical performance comparison of two medium cut-off dialyzersDetlef H Krieter, Marieke Rüth, Horst-Dieter Lemke, et al.
European Heart Journal|February 17, 2018
Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapyJonas Müntze, Tim Salinger, Daniel Gensler, et al.
International Journal of Cardiology|August 8, 2006
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trialsHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 20, 2015
Fabry disease and the heartNora Seydelmann, Christoph Wanner, Stefan Störk, et al.
Renal Failure|August 25, 2006
The renal safety profile of fluvastatin: results of a pooled analysisHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
BMC Medical Research Methodology|June 7, 2011
Understanding competing risks: a simulation point of viewArthur Allignol, Martin Schumacher, Christoph Wanner, et al.
Nephron|July 18, 2015
Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with HyperphosphatemiaJoachim Hertel, Francesco Locatelli, Goce Spasovski, et al.
Circulation|December 2, 2009
Glycemic control and cardiovascular events in diabetic hemodialysis patientsChristiane Drechsler, Vera Krane, Eberhard Ritz, et al.
BMC Medical Genetics|July 20, 2016
Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation allelesDaniel Oder, Dorothee Vergho, Georg Ertl, et al.
Pageof 79